Squarepoint’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Squarepoint’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-8	Closed	-$72K	–	3608
2021 Q3	$72K	Buy	+8	New	+$68.8K	﹤0.01%	2731
2021 Q2	–	Sell	-8	Closed	-$155K	–	3803
2021 Q1	$155K	Sell	8 -34	-81%	-$397K	﹤0.01%	2782
2020 Q4	$256K	Buy	+42	New	+$165K	﹤0.01%	2337
2020 Q2	–	Sell	-5	Closed	-$9K	–	2577
2020 Q1	$9K	Sell	5 -1	-17%	-$3.72K	﹤0.01%	1782
2019 Q4	$28K	Hold	6	–	–	﹤0.01%	2416
2019 Q3	$21K	Sell	6 -1	-14%	-$6.03K	﹤0.01%	2273
2019 Q2	$63K	Buy	+7	New	+$73.7K	﹤0.01%	2268
2018 Q2	–	Sell	-1	Closed	-$29K	–	2114
2018 Q1	$29K	Buy	+1	New	+$191K	﹤0.01%	1623

Other funds holding SEEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UIC

Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Squarepoint's SEEL Position: Q4 2021 in Review

Squarepoint sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2021, closing a stake of 8 shares — an estimated $72K sold.

Squarepoint first reported a position in SEEL in Q1 2018 and held it in 8 quarters. The position peaked at $256K in Q4 2020. 82 funds tracked by Wall St. Rank hold SEEL as of Q4 2021.

Squarepoint reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Squarepoint sold 8 Seelos Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $72K.
Squarepoint first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2018 and held it in 8 quarters.
Squarepoint's Seelos Therapeutics, Inc. Common Stock position peaked at $256K in Q4 2020.
82 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Squarepoint's 13F filing for Q4 2021, filed 14 Feb 2022.